Eptifibatide: A potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 8, 2002, Pages 1199-1210

  O'Shea, J Conor ^a   Tcheng, James E ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndromes; Glycoprotein; IIb IIIa inhibitors; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CITRATE SODIUM; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPTAPEPTIDE; INTEGRIN; PLACEBO; PYRIDINE DERIVATIVE; SNAKE VENOM; STREPTOKINASE; THROMBOCYTE RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOGEN RECEPTOR; PEPTIDE;

ACUTE HEART INFARCTION; AMINO ACID SEQUENCE; ARTERY THROMBOSIS; BLEEDING DISORDER; BLEEDING TIME; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; MORTALITY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; RISK ASSESSMENT; ST SEGMENT; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS; URINARY EXCRETION; AGED; ANIMAL; CATHETER ABLATION; CHEMISTRY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; EXPERT WITNESS; FEMALE; HEART INFARCTION; MALE; RAT;

AGED; ANIMAL; CATHETER ABLATION; CLINICAL TRIALS; CORONARY DISEASE; EXPERT TESTIMONY; FEMALE; HUMAN; MALE; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; ANIMALS; HUMANS;

EID: 0035989263     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.8.1199     Document Type: Review

References (54)

1. Coronary arteriographic findings in acute transmural myocardial infarction
2. The continuing debate: Conservative or interventional therapy for unstable coronary disease
3. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death
4. Unstable angina with fatal outcome. Dynamic coronary thrombosis leading to infarction and/or sudden death
5. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
6. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction
7. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
8. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of strokes in high risk patients
9. Congenital bleeding disorders with long bleeding time and normal platelet count. 1. Glanzmann's thrombasthenia
10. Glanzmann's thrombasthenia: New insights from an historical perspective
11. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia
12. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins
13. The formation of calcium-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis
14. Cell adhesion molecules in coronary artery disease
15. The platelet membrane glycoprotein IIb/IIIa complex
16. Platelet membrane glycoproteins
17. Critical decisions in thrombosis and hemostasis
18. Integrins: Versatility, modulation, and signaling in cell adhesion
19. GPIIb-IIIa: The responsive integrin
20. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
21. Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion
22. Synthetic peptide within cell attachment activity of fibronectin
23. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity
24. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets
25. New perspectives in cell adhesion: RGD and integrins
26. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule
27. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to activated platelets
28. The amino acid sequence of the alpha-chain of human fibrinogen
29. Gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors
30. Novel antithrombotic agents
31. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor
32. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its alpha subunit
33. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor
34. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide
35. Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: Evidence for a family of platelet aggregation inhibitors (ArgGlyAsp/fibrinogen receptor/trigramin/echistatin/kistrin)
36. Design of potent and specific integrin antagonists with high specificity for glycoprotein IIb/IIIa
37. Therapeutics I: Pharmacodynamics of the glycoprotein IIb/IIIa antagonist Integrilin: Phase I clinical studies in normal healthy volunteers
38. Platelet interactions with Dacron grafts: A model of acute thrombosis in baboons
39. Inhibition of platelet adhesion during cardiopulmonary by-pass reduces postoperative bleeding
40. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
41. The Impact II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II
42. Effect of calcium on GP IIb/IIIa interactions with Integrilin - Enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
43. Glycoprotein IIb/IIIa inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective
44. Platelet glycoprotein IIb/IIIa receptor blockade with high dose Integrilin™ in coronary intervention. Results of the PRIDE Study
45. The Esprit Investigators: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
46. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention
47. The Pursuit Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
48. Combined accelerated tissue-plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled dose ranging trial
49. Combined therapy with streptokinase and Integrilin
50. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: The Integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. The INTRO AMI Investigators
51. The Epic Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
52. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study